Replicative senescence and arteriosclerosis after kidney transplantation

Peer-reviewed author version

Replicative senescence and arteriosclerosis after kidney transplantation

Katrien De Vusser, MD[1,2]; Dries Martens[3]; Evelyne Lerut, MD PhD[4,5]; Dirk Kuypers, MD PhD[1,2]; Tim S Nawrot, PhD[3,7]; Maarten Naesens, MD PhD[1,,2]

[1] Department of Microbiology and Immunology, KU Leuven – University of Leuven, Leuven, Belgium

[2] Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium

[3] Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium

[4] Department of Imaging and Pathology, KU Leuven – University of Leuven, Leuven, Belgium

[5] Department of Pathology, University Hospitals Leuven, Leuven, Belgium

[6] Department of Abdominal Transplantation Surgery, University Hospitals Leuven, Leuven, Belgium, EU

[7] Department of Public Health and Primary Care, KU Leuven – University of Leuven, Leuven, Belgium

Corresponding author:

Prof. Dr. Katrien De Vusser

Nephrology and Renal Transplantation

University Hospitals Leuven

Herestraat 49

3000 Leuven, Belgium (EU)

Tel. +32 16 344580

Fax +32 16 344599

Email: Katrien.devusser@uzleuven.be

Word count manuscript text: 5829

1

Abstract

Background

Replicative senescence is associated with telomere shortening. In native kidneys, obtained prior to transplantation, we recently described and validated a significant association between shorter intrarenal telomere length and renal arteriosclerosis. After renal transplantation, animal experiments suggested that ischemia-reperfusion injury, acute rejection episodes, and cytomegalovirus disease associate with accelerated renal allograft senescence. The association between post-transplant events and replicative senescence has not yet been evaluated in a human setting.

Methods

In a cohort of 134 kidney allograft recipients, we performed protocol-specified renal allograft biopsies at three months, one year, two years and five years after transplantation (N=579 biopsies). We used quantitative real-time PCR to measure intrarenal relative average telomere length (T/S ratio). The association between donor and recipient demographic factors, post-transplant clinical/histological events, renal allograft histological evolution by five years post-transplant, and intrarenal telomere length at five years after transplantation was studied using multiple regression models.

Results

At 5 years after transplantation, shorter intrarenal telomere length was associated with male donor gender, and older donor age, donor history of hypertension, and donor cardiovascular risk, which confirms the associations observed in native kidneys. Recipient characteristics and post-transplant events like delayed graft function, acute rejection episodes, presence of donor-specific antibodies, cytomegalovirus disease and immunosuppressive regimen did not associate with alterations of intrarenal telomere length at 5 years**.** Independent of donor age and donor cardiovascular risk, intrarenal arteriosclerosis in protocol biopsies obtained at five years after transplantation, and progressive arteriosclerosis over time after transplantation, associated with shorter telomere length, while this was not the case for other histological lesions.

Moreover, telomere attrition augments the association between older donor age and the presence of severe arteriosclerosis. In the group with the oldest donor age and shortest telomere length, there was significantly more severe arteriosclerosis (43%) in protocol biopsies at five year after transplantation, compared to other combinations (13-28%)(p=0.001). Intrarenal arteriosclerosis at 5 years after transplantation did not associate with post-transplant clinical events.

Interpretation

We demonstrate that intrarenal telomere length at 5 years after transplantation, as marker for replicative senescence, associates with renal arteriosclerosis, and reflects kidney donor characteristics, but not post-transplant events.

Introduction

Telomeres are complexes of tandem TTAGGG repeats of 5000 to 15000 base pairs that reside at the ends of chromosomes[1]. Their main function is to cap these chromosome ends and prevent chromosomal instability[2]. Telomeres shorten by each cell division until a critical length is reached, which leads to permanent and irreversible growth arrest, referred to as replicative senescence[3]. Telomere length is a well-established marker of biological age [4]. Although telomere length is partly heritable, there are major differences in telomere length even among monozygotic twins, which illustrates that environmental factors are important in telomere attrition rate[5].

Accelerated telomere attrition plays a leading role in the development of age-related pathologies like atherosclerosis and cardiovascular disease, as was shown in large epidemiological studies[6]. Obesity and smoking are associated with leucocyte telomere attrition, as well as hypertension, insulin resistance and diabetes, male gender and lower socioeconomic status[6-12].

Recently, in a cohort of native kidneys used for transplantation, we have illustrated that telomere attrition associates with histology of arteriosclerosis[13] . Arteriosclerosis of the smaller intrarenal arteries was associated with shorter telomere length, independent of potential confounders including calendar age and cardiovascular risk, which suggests a central role of replicative senescence in the progression of renovascular disease.

Accelerated senescence after transplantation, caused by the cumulative burden of injury and the intrinsic donor characteristics, has been suggested to be one of the main drivers of graft deterioration. In animal studies, there is some evidence that ischemia reperfusion injury, acute rejection, drug toxicity and viral infections in the peri- and post-transplant period lead to accelerated senescence [14-16]. In addition, animal models illustrated that renal allograft senescence plays a role in the ability to repair and remodel the

transplanted kidneys in order to maintain tissue integrity and function[17]. It remains however unclear whether these animal data can be translated to the human situation[18].

Therefore, in the current study in human renal allograft recipients, we evaluated the association between intrarenal telomere length late after transplantation, as marker of biological age, renal allograft histology, pretransplant donor/recipient demographics, and post-transplant clinical events.

Methods

Inclusion and exclusion criteria

All prospective adult recipients of a single kidney transplant, performed between January 2006 and July 2009 at the University Hospitals Leuven (Leuven, Belgium), were eligible for this study. In the University Hospitals Leuven, renal allograft biopsies are routinely performed at time of transplantation, and at 3, 12, 24 and 60 months after transplantation, in addition to clinically indicated biopsies. We included all patients with a five-year protocol biopsy, and with a sufficient amount of good-quality kidney DNA available for evaluation of telomere length (see below). In this 5 year protocol biopsy cohort no baseline (time of transplantation) biopsies were available. The start of our baseline biopsy program started after 2009. The Ethics Committee/Institutional Review Board of the University Hospitals Leuven (Leuven, Belgium) approved this study (OG032; ML7499 and ML9785; clinicaltrials.gov NCT01331668).

Donor clinical data collection

We obtained clinical donor data from the Eurotransplant database ("Eurotransplant Donor Report"), which is maintained prospectively and is the central source of donor data for organ transplantation in the Eurotransplant region (www.donordata.eu). We collected the following data: calendar age, gender, cause of death, weight and length, living vs. deceased donor, brain death vs. cardiac death donor, body mass index, history of hypertension, diabetes mellitus, smoking, history of cardiovascular events prior to donation (including reason for death in deceased donors) and terminal serum creatinine levels before organ recovery. We estimated renal function using the 4-variable Modification of Diet in Renal Disease (MDRD) equation (estimated glomerular filtration rate; eGFR)[19].

Recipient clinical data collection

Clinical demographics of the renal allograft recipients were prospectively collected in electronic clinical

patient records and transferred to SAS data files (SAS institute, Cary NC). The following data were collected:

calendar age at time of transplantation, gender, weight and length, body mass index, new onset diabetes

mellitus after transplantation (defined as the need to start insulin treatment or oral anti diabetic medication

after transplantation), smoking after transplantation, cardiovascular events after transplantation (defined as

the occurrence of a cardiovascular event post transplantation), treated CMV disease, CMV status as a positive

CMV PCR (< 600 IU/ml /< 2.78 log IU/ml) after transplantation, the presence of one or more treated acute

rejection episode after transplantation, delayed graft function after transplantation (defined as the need for

dialysis in the first seven days after transplantation), immunosuppressive protocol, serum creatinine levels at

3, 12, 24 and 60 months after transplantation, presence of donor-specific HLA antibodies (DSA; either

pretransplant or de novo after transplantation). Post-transplant renal function was estimated by the 4-

variable Modification of Diet in Renal Disease (MDRD) equation (estimated glomerular filtration rate;

eGFR)[19].

Kidney Biopsies and Histologic evaluation

One pathologist (EL) evaluated all kidney biopsies. We stained the core biopsies with slides containing 4 to 10

paraffin sections (2 µm) with hematoxylin eosin, periodic acid–Schiff (PAS), and a silver methenamine staining

method (Jones). An immunohistochemical C4d stain (monoclonal antibody, dilution 1:500, Quidel

corporation, Santa Clara,CA) was performed on frozen tissue. The severity of histologic lesions (tubulitis,

interstitial inflammation, intimal arteritis, glomerulitis, interstitial fibrosis, tubular atrophy, arteriolar

hyalinosis, vascular intimal thickening, transplant glomerulopathy and increase in mesangial matrix), were

scored semiquantitatively according to the updated Banff criteria [20]. In addition, the total number of

glomeruli in each biopsy, and the number of globally sclerosed glomeruli, were calculated separately

(0=<25%; 1=>25%). Peritubular capillaritis was scored based on the score described in the Banff 2007

classification[21]. C4d deposition in the peritubular capillaries was scored from 0 to 3 (with 0= negative, 1= <25%, 2=25%-75% and 3= <75% of peritubular capillaries positive), given the use of immunohistochemistry on frozen tissue for this marker. Biopsy adequacy was assessed according to the Banff 1997 criteria. Only biopsies with >10 glomeruli were included for evaluation of glomerulosclerosis.

We calculated delta (Δ) histology as the semiquantitative Banff score of the histological lesion in the five-year protocol biopsy (range 0-3) – the semiquantitative Banff score of the histological lesion in the three-month biopsy. Positive values represented biopsies with progression. Zero values represented biopsies without histological progression.

Telomere Length in Kidney Biopsies

We stored half a core of the biopsies performed at 5 years after renal transplantation immediately in Allprotect Tissue Reagent (Qiagen, Venlo, The Netherlands), until extraction. We extracted DNA with the Allprep DNA/RNA/miRNA Universal Kit (Qiagen, Venlo, The Netherlands) on a QIAcube instrument (Qiagen, Venlo, The Netherlands). We determined both DNA yield (ng/µL) and purity ratios A260/280 and A260/230 using a Nanodrop ND-1000 spectrophotometer (Isogen Life Science, De Meern, the Netherlands). DNA quality needed to be within strict quality limits (yield 50 ng/µL; purity ratio range 1.5-2 and 1.5-2 for A260/280 and A260/230, respectively) for inclusion. We stored extracted DNA samples at -80°C until further use.

We measured telomere length in renal tissue samples based on a modified quantitative real-time PCR protocol[22]. Telomere lengths were expressed as the telomere repeat copy number relative to a single-copy gene (*36B4*). DNA samples were diluted to 5 ng and checked using the Quant-it PicoGreen dsDNA assay kit (lifetechnologies) to ensure uniform DNA input for PCR quantification. The telomere reaction mixture contained 1x Qiagen QuantiTect SYBR Green Mastermix, 2.5 mM of dithiothreitol, 300 nM of telg primer (5'-

ACACTAAGGTTTGGGTTTGGGTTT- GGGTTTGGGTTAGTGT-3'), and 900 nM of telc primer (5'- TGTTAGGTATCCC-TATCCCTATCCCTATCCCTATCCCTAACA-3'). Telomere PCR conditions were: 1 cycle at 95°C for 10 min, followed by 2 cycles of 15 sec at 94°C and 2 min at 49°C, and 30 cycles of 15 sec at 94°C, 20 sec at 62°C and 1 min 40 sec at 74°C. The single-copy gene (36B4) reaction mixture contained 1x Qiagen QuantiTect SYBR Green Mastermix, 300nM 36B4U primer (5'-CAGCAAGTGGGAAGGTGTAATCC-3') and 500nM 36B4D primer (5'-CCCATTCTATCATCAACGGGTACAA-3'). Single-copy gene PCR conditions were: 1 cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, and 58°C for 1 min 10 sec. Samples were run in triplicate on an Applied Biosystems 7900HT Fast Real-Time PCR system in a 384-well format. We calculated PCR efficiency based on a 6-point serial dilution (20ng-0.08ng) of pooled kidney tissue DNA. PCR efficiency was accepted between limits of 90-110%. We calculated relative average telomere lengths using qBase software (Biogazelle, Zwijnaarde, Belgium). Relative telomere length was expressed as the ratio of telomere copy number to single-copy gene number (T/S), relative to the average T/S ratio of the entire population (N=134). We achieved a coefficient of variation within telomere and single-copy gene triplicates of 0.70% and 0.51% respectively. All biopsies included passed quality control for assessment of intra-renal telomere length. The results for T/S ratio were normally divided and in the same order of magnitude as the results of our recently published paper [13], where the results were [10]log transformed because T/S ratios were not normally distributed in this prior publication. In the current analyses, no log transformation of the data was necessary.

We evaluated accelerated biological aging by calculating delta (Δ) renal biological age - donor calendar age. Δ (range -3 – 3) was calculated using the difference of quartile telomere length (0 = longest telomere length, 3 = shortest telomere length) - quartile calendar age (0 = youngest age group, 3 = oldest age group). Positive values represented biopsies with older biological than calendar age. Negative values represented biopsies with younger biological age than calendar age.

Statistical analysis

We assessed the associations between the clinical donor and recipient demographics, telomere length and renal histology by linear or regression analysis, as well as spearman correlations. We used multiple linear regressions, with backward parameter selection, to model the determinants of intrarenal telomere length at 5 years after transplantation. For backward parameter selection, we considered the following variables for entry into the model for the determinants of intrarenal telomere length at 5 years: donor calendar age, donor gender, donor history of hypertension, donor history of diabetes mellitus and donor body mass index, donor history of cardiovascular events, living vs. deceased donor, brain-death vs. cardiac death and renal function (eGFR), recipient calendar age, recipient gender, recipient history of diabetes mellitus, recipient history of cardiovascular events, cold ischemia time, delayed graft function, treated cytomegalovirus (CMV) disease, the presence of one or more treated acute rejection episodes after transplantation (either T-cell mediated or antibody-mediated), biopsy-proven T cell mediated rejection, biopsy-proven antibody-mediated rejection, renal function at 3, 12, 24 and 60 months after transplantation (eGFR (mL/min/1.73m^2), presence of DSA (pretransplant or de novo post-transplant) and immunosuppressive protocol. We used multiple linear regressions, with backward parameter selection, to model the determinants of the different chronic histological lesions, including the same explanatory parameters.

All tests were two-sided and p values of less than 0.05 were considered to indicate statistical significance. The results are expressed as numerical values and percentages for categorical variables and as mean ± standard deviation for continuous variables, unless otherwise specified. We performed the analyses with SAS (version 9.2; SAS institute, Cary, NC) and GraphPad Prism (version 5.00; GraphPad Software, San Diego, CA) software.

Results

Population characteristics

Between January 2006 and July 2009, 487 renal transplantations were performed at the University Hospitals
Leuven, of which 213 underwent a five-year protocol biopsy. Of these biopsies, 134 had sufficient amount of
good-quality renal DNA available for evaluation of telomere length. In this cohort, 579 (N= 125 3 months, N=
126 12 months, N= 134 24 months and N= 134 60 months and 73 indication) biopsies were available for
histological evaluation. **Table 1** summarizes the characteristics of our cohort and the histology of the biopsies
that were included. In total 11/579 biopsies (1.9%) were inadequate according to these criteria and the
individual histological features that were not interpretable were excluded from the analyses. All the patients
included in this study had an adequate five-year protocol biopsy.

In this study there were 353 excluded patients (79 patients with 5 year protocol biopsy but insufficient
amount of good-quality renal DNA available for evaluation of telomere length + 274 patients without 5 year
protocol biopsy).

There were no significant differences between the included patients with a 5 year protocol biopsy available
and excluded patients. The demographics of the excluded patients are summarized in **Table 2.**

Determinants of intrarenal telomere length

Mean intrarenal log T/S ratio of telomere length at 5 years after transplantation was 0.94±0.18 (range 0.54 to
1.6). Shorter telomere length correlated with older calendar age (r=0.28; p=0.006)(**Table 3**; **Figure 1**). Donor
history of hypertension *vs.* no hypertension (T/S ratio 0.88±0.22 vs. 0.98±0.24 with vs. without hypertension;
p=0.03) and donor history of cardiovascular events vs. no history (T/S ratio 0.91±0.20 vs. 1.01±0.19with vs.
without history of cardiovascular events; p= 0.002) were also associated with shorter telomere length (**Table
3**)(**Figure 1**). Male donor kidneys had a shorter intrarenal telomere length compared to female donor kidneys
(T/S ratio 0.92±0.19 vs. 0.10±0.22; p= 0.02). Other clinical demographics, including history of diabetes

mellitus, history of smoking, living versus deceased donation, brain death vs. cardiac death, donor body mass index, cold ischemia time and donor terminal eGFR were not associated with telomere length.

In univariate analysis, intrarenal telomere length at five years after transplantation inversely correlated with older recipient calendar age (r=-0.24, p=0.03). None of the other recipient factors or post-transplant events associated with intrarenal telomere length at 5 years (**Table 3**). In multivariate linear regression analysis, older calendar age, donor history of cardiovascular events, male donor gender and donor history of hypertension were independent explanatory factors for shorter intrarenal telomere length at five years after transplantation (**Table 3**).

Intrarenal telomere length, clinical demographics and renal histology

In univariate analysis, there was a borderline significant association between intrarenal telomere length at 5 years after transplantation and intrarenal arteriosclerosis (p= 0.09)(**Table 4**). If intrarenal arterioscleroris was dichotomized in severe arteriosclerosis vs. non severe arteriosclerosis (cv 0-1 vs. cv 2-3), there was a significant association with intrarenal telomere length (T/S ratio 0.99±0.19 vs. 0.91±0.27 in cv=2-3 vs. cv=0-1; p=0.03). There was no association between intrarenal telomere length and the other histological lesions (**Table 4**). Given the collinearity of telomere length with donor demographics (see above), a multivariate analysis was performed, with adjustment for donor age, donor history of hypertension, donor cardiovascular risk and male donor gender, and including an interaction term between telomere length and donor age. In this analysis, intrarenal telomere length significantly and independently associated with intrarenal arteriosclerosis, but not with other histological lesions (**Table 4**). Moreover, presence of severe arteriosclerosis in renal biopsies associated with donor age (donor age 50.81±18.0 vs. 42.81±15.2 in cv=2-3 vs. cv=0-1; p=0.003) and donor cardiovascular risk (56% cv vs. 37% cardiovascular risk in presence vs. absence of severe arteriosclerosis; p=0.05)(**Figure 2**).

The significant interaction between donor age and telomere length for association with arteriosclerosis illustrates that the association between intrarenal telomere length and arteriosclerosis depends on donor age. To further elucidate this interaction between calendar age and telomere length, we calculated Δ accelerated biological aging. This parameter associated significantly with the presence of arteriosclerosis at 5 years after transplantation (range -3 – 3; p=0.001)(**Figure 3A**). Telomere attrition augments the association between older donor age and the presence of severe arteriosclerosis. In the group with the oldest donor age and shortest telomere length, there was significantly more severe arteriosclerosis (43%) in protocol biopsies at five year after transplantation, compared to other combinations (13-28%)(**figure 3B**).

Progressive arteriosclerosis and telomere length

Next, we evaluated delta histology over time after transplantation (**Table 1; Figure 3C)**. At 3 months, severe arteriosclerosis was present in 14.4 % of the biopsies (18/125). At 5 years, severe arteriosclerosis was present in 27.6% (37/134) of the biopsies. Delta cv score was ≥ 1 in 42% of patients (53/125). Kidneys with progression of arteriosclerosis had a significantly shorter telomere length at 5 years compared to kidneys without progressive arteriosclerosis (T/S ratio 0.91±0.19 vs. 1.00±0.21; with or without progression p=0.005)(**Figure 3D**). In addition, arteriosclerosis progression was associated with older donor age (48.8±17.1 vs. 42.6±18.3 with or without progression; p=0.02) and history of cardiovascular events (0.58±0.3 vs. 0.39±0.2 with or without progression; p=0.03). Progression of interstitial fibrosis/tubular atrophy (IFTA) associated with older donor age (donor age 47.5±161 vs. 41.3±19.0 years with vs. without IFTA; p=0.01) but not with telomere length. Progression of the other histological lesions (glomerulosclerosis, arteriolar hyalinosis) did not associate with donor age or shorter telomere length.

Sensitivity analysis

To investigate the robustness of our findings, we performed a sensitivity analyses in the subgroup male

kidney donors and female kidney donors. In the male subgroup, telomere length correlated significantly with

donor age (r=-0.4 p=0.002) and with history of cardiovascular events (0.92 ± 0.27 vs. 1.1 ± 0.39 with vs.

without history of cardiovascular events p=0.0004).

In univariate analysis, there was no association between intrarenal telomere length at 5 years after

transplantation and severe arteriosclerosis. When multivariate analysis was performed, with adjustment for

an interaction term between telomere length and donor age, intrarenal telomere length significantly and

independently associated with intrarenal arteriosclerosis (T/S ratio 0.94±0.17 vs. 0.88±0.14 in cv=2-3 vs. cv=0-

1; p=0.05). Also in the female subgroup, telomere length correlated significantly with donor age (r=-0.38

p=0.003), and also with history of cardiovascular events (0.97 ± 0.05 vs. 1.0 ± 0.04 with vs. without history of

cardiovascular events p=0.5). When multivariate analysis was performed, with adjustment for an interaction

term between telomere length and donor age, the association between intrarenal telomere length and

intrarenal arteriosclerosis reached borderline significance (T/S ratio 0.94±0.15 vs. 1.01±0.28 in cv=2-3 vs.

cv=0-1;p=0.07).

Telomere length and graft function or graft outcome

After the 5-year protocol biopsy, 3.7% of recipients (N=5) experienced graft failure: two recipients returned to

dialysis due to graft loss and three recipients died with a functioning graft. For this, the association between

telomere length and graft survival could not be evaluated. There was no association between telomere length

and renal function at 3 months, 12, 24 and 60 months (**Table 3**).

Discussion

In the current study, we demonstrated that the associations between intrarenal telomere length and older donor calendar age, donor history of hypertension and donor cardiovascular events remain present many years after transplantation, irrespective of post-transplant injury processes. This illustrates the long-term, persisting impact of donor characteristics on kidney graft telomere length, independent of immune and non-immune injury processes after transplantation, such as ischemia reperfusion injury, acute rejection and viral infections. Moreover, we confirmed the significant relation between telomere length (biological aging) and renovascular disease (arteriosclerosis) in our five-year protocol biopsy cohort. Also here, despite significant progression of arteriosclerosis over time after transplantation, this progression related to pretransplant donor factors, hypertension and cardiovascular risk, and not to post-transplant injury processes.

Recently, we illustrated and validated that shorter (intrarenal) telomere length associates with older calendar age, history of hypertension and cardiovascular events in a cohort of native kidneys before transplantation [13]. This association between shorter telomere length and clinical cardiovascular disease has also been described in the cardiovascular field [6, 9, 23]. Moreover, we described that arteriosclerosis in smaller intrarenal arteries of native kidneys is associated with shorter telomere length, suggesting a significant relation between replicative senescence or biological aging and renovascular disease [13].

Previous literature suggested that after kidney transplantation, immune and non-immune injury to the kidney can cause accelerated aging of the graft[16, 18]. An observational study in allogeneic bone marrow transplants found a 15 year acceleration of telomere shortening in the grafted cells[24]. In transplanted renal cells, there is evidence for an increased cell turnover at the time of transplantation and a phase of increased cell regeneration directly after transplantation that correlates with cold ischemia time[14, 15]. Also a small study showed that shorter telomere length in biopsies obtained at implantation was associated with lower

graft function at 12 months after transplantation, but no correlation with p21 or p53 was found [17]. Kotsch

et al found a significant association between NKG2D and CDKN2A expression and creatinine levels 24 months

after transplantation but only NKG2D remained significantly predictive in a multivariate model at 12 months

[25].

Stenvinkel et al proposed the hypotheses of increased telomere attrition because of the immunosuppressive

treatment (more specifically the influence of MMF) in a small study of 47 TX patients and a control group[26].

In human renal transplants with interstitial fibrosis/tubular atrophy and impaired graft function, Melk et al

described increased p16 expression, suggestive of accelerated senescence [27], although this is a non-specific

marker, largely telomere-independent. Furthermore, a rapid increase in p16 expression after transplantation

was described in murine kidney grafts, which was most pronounced in older animals[28]. Notwithstanding the

aforementioned studies, suggesting the presence of post-transplant accelerated senescence, no definite

proof of accelerated telomere shortening has been described in human kidney grafts. In contrast, our findings

illustrate that post-transplant telomere length, even five years after transplantation, is not primarily

dependent on the immune and non-immune factors associated with kidney transplantation. These findings

question the hypothesis of accelerated replicative senescence as consequence of specific injury processes

after renal transplantation.

Interestingly, the current study sheds new light on the risk factors for arteriosclerosis (vascular intimal

thickening) after renal transplantation. Both in zero-time biopsies[13] and in the current study in biopsies at

5 years after transplantation, intrarenal telomere length significantly associated with arteriosclerosis.

Moreover, also accelerated biological age, expressed as the difference between biological age and calendar

age, associated with intrarenal arteriosclerosis. The robust association of telomere shortening and histology of arteriosclerosis could explain the previously observed association between shorter telomere length and clinical cardiovascular disease, also present in our study. Similarly, in a large cohort study, Loupy et al recently described a significant association between graft arteriosclerosis and donor-related cardiovascular risk factors (age, diabetes mellitus, cardiovascular risk and hypertension). These authors hypothesized that post-transplant accelerated arteriosclerosis may be partially donor-transmitted [29]. Taken together with our findings, this is convincing evidence that post-transplant arteriosclerosis is, at least partly, a senescence phenomenon. Nevertheless, also other factors likely play a role as well. The study by Loupy et al has illustrated that antibody-mediated injury could contribute to graft arteriosclerosis[29]. In our analysis, which is underpowered for this analysis due to very low prevalence of patients with donor-specific antibodies, we could not confirm a role of circulating donor-specific anti-HLA antibodies in the development of arteriosclerosis.

Our study has some limitations. Although donor clinical demographics were collected prospectively, some kidney donor parameters that could be of importance could have been recorded incompletely. This could explain the lack of association between telomere shortening and diabetes mellitus, as was described previously[7, 12]. In addition, we are aware of the fact that our study only includes a relatively low number of patients, with inherent selection bias by the inclusion of only patients with at least 5-year graft survival. In our hospital, 5-year protocol biopsies were routinely performed between 2009 and 2014, but even in this situation many pati^)-ents decline participation. Obviously, patients who did not undergo the 5-year protocol biopsy, who lost their graft, or who died before 5 years after transplantation, were not included in this study. The exclusion of these patients could have impacted the results, likely by underestimation of the histological lesions at 5 years and of the most deleterious post-transplant events (CMV disease, therapy-resistant acute rejection etcetera). Moreover, the low number of patients with antibody-mediated rejection

or donor-specific antibodies implies that our study is underpowered to detect an association between these parameters and telomere attrition or 5-year histology. Absence of association in our analysis therefore should not be over-interpreted. We also recognize that, because of the selected study population, associations between telomere length and graft survival could not be explored. Not all ageing processes are mediated by telomere attrition, and no conclusions can be drawn regarding the impact of post-transplant events on these other ageing mechanisms. Finally, the study design does not allow drawing conclusions on causality between donor characteristics, post-transplant telomere attrition and post-transplant histology.

In conclusion, we demonstrated that intrarenal telomere length at 5 years after transplantation, as marker of replicative senescence, is associated with donor characteristics, but not with post-transplant events. Similar to what we observed in native kidneys, post-transplant renal arteriosclerosis primarily represents biological organ aging. Further study is necessary to elucidate whether telomere attrition plays a role in the long-term outcome after kidney transplantation.

Table 1. Demographics and histology of the subjects and biopsies included in this study.

Data are expressed as mean ± standard deviation unless otherwise specified; [#]eGFR was calculated using the MDRD formula [19, 30].

Legend: CsA = cyclosporine, MMF= mycophenolate mofetil, Cs= Corticosteroids, TAC =Tacrolimus

Demographics	Percentage (N) or mean ± Standard Deviation
N	134
Donor Characteristics	
Donor Calendar Age (years)	44.5 ± 14.8
Male Gender % (N)	53.7 % (72)
Deceased Donor % (N)	92.6% (124)
Brain Death / Cardiac Death	83.0%(103)/14.0%(21)
History of Hypertension % (N)	18.7% (25)
History of Diabetes Mellitus % (N)	2.2% (3)
History of Smoking % (N)	25.7% (34)
Body Mass Index (kg/m^2)	25.5 ± 4.3
History of Cardiovascular Events % (N)	38.1% (51)
Cold Ischemia Time (Hours)	14.5 ± 6.4
Recipient Characteristics	
Recipient Calendar Age (years)	51.4 ± 12.8
Male Gender % (N)	53% (71)
Repeat transplantation % (N)	8.1%(11)
Pretransplant Donor-Specific Antibodies % (N)	13.4% (18)
Post-Transplant Factors	
Delayed Graft Function	10.4% (14/134)
Immunosuppressive Protocol (CsA-MMF-Cs / TAC-MMF-Cs / other)	56/74/4
Presence of One or More Treated Acute Rejection Episodes after Transplantation % (N)	14.9% (20)
Biopsy-Proven Acute Cellular Rejection % (N)	23.8% (32)
Acute Antibody-Mediated Rejection % (N)	2% (3)
Post-transplant Diabetes Mellitus % (N)	27.6% (37)
Body Mass Index at 5 years post-transplant (kg/m^2)	24.9 ± 5.5
Post-transplant Cardiovascular Events % (N)	26.1% (35)

Serum Creatinine 3 months (mg/dl)	1.62 ± 0.45				
eGFR 3 months (mL/min/1.73m^2)#	46.8 ± 15.0				
Serum Creatinine 12 months (mg/dl)	1.44 ± 0.38				
eGFR 12 months (mL/min/1.73m^2)#	52.8 ± 15.3				
Serum Creatinine 24 months (mg/dl)	1.46 ± 0.23				
eGFR 24 months (mL/min/1.73m^2)#	53.0 ± 17.1				
Serum Creatinine 60 months (mg/dl)	1.53 ± 0.44				
eGFR 60 months (mL/min/1.73m^2)#	49.3 ± 14.9				
<mark>CMV Disease</mark>	12 (3.4%)				
<mark>CMV PCR</mark> (< 600 IU/ml /< 2.78 log IU/ml)	35 (9.9%)				
Biopsy characteristics	**3 months**	**1 years**	**2 years**	**5 years**	**Indication**
N	125	126	134	134	73
Telomere Length (T/S ratio)	-	-	-	0.94 ± 0.18	-
Banff Arteriolar Hyalinosis grade % (N)	0 = 76.0% (95)	0 = 81.7% (103)	0 = 72.4% (97)	0 = 32.0% (43)	0 = 86.4% (63)
	1 = 20.8% (26)	1 = 15.1% (19)	1 = 22.4% (30)	1 = 36.6% (49)	1 = 6.8% (5)
	2-3 = 3.2% (4)	2-3 = 3.2% (4)	2-3 = 5.2% (7)	2-3 = 31.4% (42)	2-3 = 6.8% (5)
Banff Interstitial Fibrosis/Tubular Atrophy grade % (N)	0 = 79.2% (99)	0 = 55.6% (70)	0 = 47.0% (63)	0 = 36.6% (49)	0 = 83.6% (61)
	1 = 19.2% (24)	1 = 38.1% (48)	1 = 36.6% (49)	1 = 37.3% (50)	1 = 11.0% (8)
	2-3 = 1.6% (2)	2-3 = 6.3% (8)	2-3 = 16.4% (22)	2-3 = 26.1% (35)	2-3 = 5.4% (4)
Banff Arteriosclerosis grade % (N)	0 = 52.8% (66)	0 = 46.0% (58)	0 = 44.7% (60)	0 = 36.6% (49)	0 = 65.8% (48)
	1 = 32.8% (41)	1 = 34.9% (44)	1 = 29.9% (40)	1 = 35.8% (48)	1 = 13.7% (10)
	2-3 = 14.4% (18)	2-3 = 19.1% (24)	2-3 = 25.4% (34)	2-3 = 27.6% (37)	2-3 = 20.5% (15)
Presence of >25% Glomerulosclerosis% (N)	0 = 94.4% (118)	0 = 93.7% (118)	0 = 84.3% (113)	0 = 67.9% (91)	0 = 94.5% (69)
	1 = 5.6% (7)	1 = 6.3% (8)	1 = 15.7% (21)	1 = 32.1% (43)[31]	1 = 5.5% (4)
Biopsy-Proven Acute Cellular Rejection %	5.6% (7)	2.4% (3)	0.1% (1)	0.1% (1)	28.7% (21)

(N)					
Acute Antibody-Mediated Rejection % (N)	0.1%(1)	-	-	-	2.7%(2)
Delta Histology progression (5 Years - 3 Months)					
Delta Arteriolar Hyalinosis Grade ≥ 1 % (N)	60.8 % (76)				
Delta Interstitial Fibrosis/Tubular Atrophy grade ≥ 1 % (N)	59.2 % (74)				
Delta Arteriosclerosis grade ≥ 1 % (N)	42.4% (53)				
Delta Presence of >25% Glomerulosclerosis ≥ 1 % (N)	29.6 % (37)				

Table 2. Demographics and histology of the subjects and biopsies excluded in this study.

Data are expressed as mean ± standard deviation unless otherwise specified; #eGFR was calculated using the MDRD formula [19, 30].

Legend: CsA = cyclosporine, MMF= mycophenolate mofetil, Cs= Corticosteroids, TAC =Tacrolimus

Demographics	Percentage (N) or mean ± Standard Deviation
N	353
Donor Characteristics	
Donor Calendar Age (years)	44.6 ± 14.7
Male Gender % (N)	54.9 % (195)
Deceased Donor % (N)	94.6% (334)
Brain Death / Cardiac Death	85.3%(285)/14.7%(49)
History of Hypertension % (N)	20.2% (71)
History of Diabetes Mellitus % (N)	4.9% (14)
History of Smoking % (N)	22.9% (81)
Body Mass Index (kg/m^2)	25.6 ± 4.2
History of Cardiovascular Events % (N)	40.2% (142)
Cold Ischemia Time	14.2 ± 6.0
Recipient Characteristics	
Recipient Calendar Age (years)	51.0 ± 11.6
Male Gender % (N)	56.9% (201)
Repeat transplantation % (N)	14.4%(51)
Post-Transplant Factors	
Delayed Graft Function	16.4% (58)
Immunosuppressive Protocol (CsA-MMF-Cs / TAC-MMF-Cs / other)	132/198/23
Presence of One or More Treated Acute Rejection Episodes after Transplantation % (N)	16.1% (57)
Biopsy-Proven Acute Cellular Rejection % (N)	24.0% (85)
Acute Antibody-Mediated Rejection % (N)	2% (6)
Post-transplant Diabetes Mellitus % (N)	30.2% (106)
Body Mass Index at 5 years post-transplant (kg/m^2)	25 ± 5.5
Post-transplant Cardiovascular Events % (N)	27.7% (98)
Serum Creatinine 3 months (mg/dl)	1.63 ± 0.49
eGFR 3 months (mL/min/1.73m^2)#	47 ± 17.3
Serum Creatinine 12 months (mg/dl)	1.43 ± 0.41
eGFR 12 months (mL/min/1.73m^2)#	55.0 ± 15.4
Serum Creatinine 24 months (mg/dl)	1.43 ± 0.39
eGFR 24 months (mL/min/1.73m^2)#	55.0 ± 17.3

| Serum Creatinine 60 months (mg/dl) | 1.47 ± 0.46 |
| eGFR 60 months (mL/min/1.73m^2)# | 53.7.3 ± 13.6 |

TABLE 3. Clinical determinants of telomere length (log T/S) in five-year protocol biopsies (N=134).

Univariate analyses were assessed by linear regression. Multiple linear regression, with backward parameter selection, was used to model the determinants of telomere length. *These parameters were included in the multivariate models, but were not retained in the final model after backward parameter selection. ** Effect sizes (SE) express the change in log T/S ratio associated with given changes in parameters. ^Defined as the need for dialysis within the first 7 days after transplantation.

Parameter	Univariate linear regression			Multivariate linear regression		
	Parameter estimate	Standard Error	P value	Parameter estimate	Standard Error	P value
Donor Characteristics						
Donor Age (per Year)	-0.003	0.001	0.006	-0.003	0.001	0.01
Donor Gender (Female)	0.08	0.04	0.02	0.1	0.04	0.002
Heart Beating Donor/Non Heart Beating Donor*	0.02	0.05	0.56			
Living Donor/Deceased Donor*	-0.01	0.06	0.84			
History of Hypertension	-0.01	0.04	0.02	-0.1	0.04	0.03
History of Diabetes Mellitus*	0.20	0.21	0.4			
History of Smoking*	-0.002	0.04	0.04			
Body Mass Index (kg/m^2) *	-0.002	0.004	0.57			
History of Cardiovascular Events	-0.11	0.03	0.002	-0.12	0.04	0.001
eGFR (mL/min/1.73m2)	0.00	0.00	0.57			
Recipient characteristics						
Recipient Age (years)*	-0.003	0.001	0.05			
Recipient Gender (Female)						
CMV Disease	-0.06	0.05	0.25			
Presence of one or more Treated Acute Rejection Episodes after Transplantation *	-0.02	0.04	0.6			

Biopsy-proven Acute Cellular Rejection	-0.003	0.03	0.9			
Acute Antibody-Mediated Rejection	0.01	0.06	0.8			
Delayed Graft Function^	-0.08	0.05	0.1			
Pretransplant Donor-Specific Antibody Presence	0.05	0.05	0.4			
Immunosuppressive Protocol (CsA-MMF-CS versus TAC-MMF-Cs)	0.1	0.03	0.02			
eGFR (mL/min/1.73m2) 3 Months after TX	0.00	0.00	0.5			
eGFR (mL/min/1.73m2) 1 Year after TX	-0.05	0.04	0.1			
eGFR (mL/min/1.73m2) 2 Year after TX	-0.05	0.03	0.2			
eGFR (mL/min/1.73m2) 5 Years after TX	0.00	0.002	0.7			
Cold Ischemia Time*	-0.01	0.00	0.07			
Cardiovascular Events after Transplantation*	-0.05	0.04	0.2			
Post-transplant Diabetes Mellitus *	-0.03	0.03	0.4			

TABLE 4. Clinical determinants of histological lesions in five-year protocol biopsies (N=134). Multiple linear regression with backward parameter selection was used to model the determinants of the five years histological lesions. Multivariate analyses presented in this table were performed on 134 subjects. Interaction terms for donor age and donor telomere length were included in the multivariate model (chi square statistical test). The associations between the histological lesions, telomere length and donor age were adjusted for donor calendar age, donor gender, donor history of hypertension, donor history of diabetes mellitus, donor body mass index, donor history of cardiovascular events,

	Univariate linear regression			Multivariate linear regression		
IF/TA grade (Banff Score)	**Parameter estimate**	**Standard Error**	**P value**	**Parameter estimate**	**Standard Error**	**P value**
Telomere length (T/S)						
Donor age (years)	0.01	0.006	0.002	0.02	0.006	0.004
Donor age (years) x Telomere Length						
Arteriolar hyalinosis grade (Banff)	**Parameter estimate**	**Standard Error**	**P value**	**Parameter estimate**	**Standard Error**	**P value**
Telomere length (T/S)						
Donor age (years)	0.01	0.005	0.02			
Donor age (years) x Telomere Length						
Arteriosclerosis	**Parameter estimate**	**Standard Error**	**P value**	**Parameter estimate**	**Standard Error**	**P value**
Telomere length (T/S)	-0.4	0.24	0.09	-0.9	0.003	0.0001
Donor age (years)	0.02	0.005	0.0003	0.02	0.3	0.003
Donor age (years) x Telomere Length				0.02	0.005	0.0005
Glomerulosclerosis	**Parameter estimate**	**Standard Error**	**P value**	**Parameter estimate**	**Standard Error**	**P value**
Telomere length (T/S)						
Donor age (years)	0.005	0.003	0.08	0.01	0.002	0.02
Donor age (years) x Telomere Length						

FIGURE 1. Relation between telomere length and (A) donor cardiovascular risk, (B) donor calendar age, (C) donor history of hypertension and

(D) donor gender. The p-values represent non-parametric ANOVA. The horizontal lines within the boxes indicate means, the upper and lower

ends of the boxes indicate standard deviations, and the whiskers indicate 95th percentiles.

FIGURE 2. Relation between severe intrarenal arteriosclerosis in the five year protocol biopsy and (A) telomere length in the five year protocol

biopsy, (B) interaction term (telomere length X donor age), (C) donor age, (D) donor history of cardiovascular risk and (E) donor history of

hypertension. The p-values represent non-parametric ANOVA. The horizontal lines within the boxes indicate means, the upper and lower ends of

the boxes indicate standard deviations, and the whiskers indicate 95th percentiles. Severe arteriosclerosis was defined as Banff cv score 2-3.

FIGURE 3.

(A) Relation between accelerated aging and presence of arteriosclerosis in the five-year protocol biopsy. Accelerated biological aging was

evaluated by calculating delta (Δ) biological age - calendar age. Δ (range -3 – 3) was calculated using the difference of quartile telomere length (0

= longest telomere length, 3 = shortest telomere length) - quartile calendar age (0 = youngest age group, 3 = oldest age group). The p-values

represent non-parametric ANOVA.

(B) The correlation between telomere length and donor age in the five-year protocol biopsies with and without presence of severe

arteriosclerosis. The percentage indicates the amount of biopsies with presence of severe arteriosclerosis (cv = 2-3) in the different groups

(group 1= age < 47,TL ≤ 0.94; group 2= age < 47, TL > 0.94; group 3= Age ≥ 47, TL > 0.94; group 4= Age ≥ 47, TL < 0.94). Severe arteriosclerosis was

defined as Banff cv score 2-3. The p-values represent chi-squaere testing between group 4 vs. group 3 (p=0.001); group 4 vs. group 1 (p<0.0001).

(C) The evolution of chronic histological lesions between 3 months and 5 years after transplantation transplantation. The p-values represent

represents non-parametric ANOVA.

 (D) Relation between progression of intrarenal arteriosclerosis and intrarenal telomere length in the five-year protocol biopsies. Delta

histology was calculated as the severity of the histological lesion in the five-year protocol biopsy – the severity of the histological lesion in the

three-month biopsy (range 0-3). Positive values represented biopsies with progression. Zero values represented biopsies without histological

progression. The p-value represents non-parametric ANOVA.

The horizontal lines within the boxes of the box-whisker plots in this figure indicate means, the upper and lower ends of the boxes indicate

standard deviations, and the whiskers indicate 95th percentiles.

REFERENCES

1. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192: 547-56.

2. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353-65

3. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains.

Exp Cell Res. 1961; 25: 585-621.

4. Wong J.M. and Collins K., Telomere maintenance and disease. Lancet, 2003. 362(9388): p. 983-8.

5. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet 2004; 363: 507-10.

6. Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol 2013; 10: 274-83.

7. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366: 662-4.

8. Demissie S, Levy D, Benjamin EJ, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging cell 2006; 5: 325-30.

9. Fitzpatrick AL, Kronmal RA, Gardner JP, et al. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol 2007; 165: 14-21.

10. Nawrot TS, Staessen JA, Holvoet P, et al. Telomere length and its associations with oxidized-LDL, carotid artery distensibility and smoking. Front Biosci 2010; 2: 1164-8.

11. Cherkas LF, Hunkin JL, Kato BS, et al. The Association Between Physical Activity in Leisure Time and Leukocyte Telomere Length. Arch intern Med 2008; 168: 154-8.

12. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere shortening and oxidative DNA damage in Type 2 Diabetes. Diabetes Care 2006; 29: 283-9.

13. De Vusser K, Pieters N., Janssen B, Lerut E, Kuypers D, Jochmans I, Monbalieu D, Pirenne J, Nawrot T, Naesens M. Telomere length, cardiovascular risk and arteriosclerosis in human kidneys: an observational cohort study. Aging (Albany NY), 2015. 7(10).

14. Oberbauer R, Rohrmoser M, Regele H, Muhlbacher F, Mayer G. Apoptosis of tubular epithelial cells in donor kidney biopsies predicts early renal allograft function. JAmSocNephrol 1999;10:2006-13.

15. Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I, Torras J, Sola A. Macrophage involvement in the kidney repair phase after ischaemia/reperfusion injury. J Pathol 2008;214:104-13.

16. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. JAmSocNephrol 1999;10:167-81.

17. Koppelstaetter C, Schratzberger G, Perco P, et al. Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation. Aging cell 2008;7:491-7.

18. Naesens M. Replicative senescence in kidney aging, renal disease, and renal transplantation. Discov Med 2011;11:65-75.

19. Levey AS, Greene T, Kusek J, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. Journal of the American Society of Nephrology : JASN 2000;11:A0828.

20. Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant. 2014;19(3):315-22.

21. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney international 1999;55:713-23.

22. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003;361:393-5.

23. Fuster DJ, Andrés V. Telomere dysfunction in hypertension. Journal of Hypertension 2007;25.:2185-92.

24. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998;351:178-81.

25. Günther J, Sattler A, Ebner S, Ritschl PV, Pascher A, Pratschke J, Kotsch K. Identification of the activating cytotoxicity receptor NKG2D as a senescence marker in zero-hour kidney biopsies is indicative for clinical outcome. Kidney International 2017;1447-1463.

26. Luttropp K, McGuinness D, Wennberg L, Curley H, Quasim T, Genberg H, Sandberg J, Sönnerborg I, Schalling M, Qureshi AR, Bárány P, Shiels PG, Stenvinkel P. Increased Telomere Attrition After Renal Transplantation-Impact of Antimetabolite Therapy. Transplant Direct. , 2016. **2**(12).

27. Melk A, Schmidt BM, Vongwiwatana A, Rayner DC, Halloran PF. Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney. Am J Transplant 2005;5:1375-82.

28. Melk A, Schmidt BM, Takeuchi O, Sawitzki B, Rayner DC, Halloran PF. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney International 2004;65:510-20.

29. Loupy A, Vernerey D, Viglietti D, et al. Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies. Circulation research 2015;117:470-82.

30. Levey AS, Tom Greene, Stevens LA, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. In: Ann Intern Med. ; 2006:247-54.